Strategic acquisitions Lonza is actively expanding through acquisitions and HPAPI facility upgrades, signaling a growing need for integration services, compliance support, and scalable manufacturing partnerships for high potency APIs.

HPAPI leadership With competition intensifying in HPAPI outsourcing and Lonza expanding capacity in the US, there is a sales opportunity to offer specialized process development, regulatory alignment, and facility biotech support tailored to HPAPI production.

Adjacency partnerships Lonza is collaborating on next generation ADC therapies and ECM-targeted approaches, indicating demand for high-value biologics development, analytical services, and advanced bioconjugation capabilities.

US expansion Investments to modernize and expand US production facilities create potential for local supply chain solutions, shipping/logistics optimization, and on-site support for biologics and specialty ingredients programs.

Digital & analytics Lonza’s tech stack and emphasis on analytics platforms suggest opportunities for enhanced digital tooling, automation modernization, data integration, and scalable GMP-compliant workflows to boost productivity.